loader image
Saturday, November 22, 2025
75.3 F
McAllen
- Advertisement -

$7.4 Bil­lion Set­tle­ment With Purdue Pharma in Opi­oid Epidemic

Translate to Spanish or other 102 languages!

exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
- Advertisement -

Texas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. 

Purdue, under the Sacklers’ leadership, invented, manufactured, and aggressively marketed opioid products for decades, fueling waves of addiction and overdose deaths across the country. The settlement ends the Sacklers’ control of Purdue and their ability to sell opioids in the United States. Further, it will deliver funding directly to communities across the country over the next 15 years to support opioid addiction treatment, prevention, and recovery programs. The $7.4 billion settlement in principle, the nation’s largest settlement to date with individuals responsible for contributing to the opioid crisis, comes after the United States Supreme Court overturned a prior multistate settlement with the Sacklers and Purdue in June 2024.

“For years, I have aggressively worked to hold Purdue Pharma and other corporations accountable for their roles in creating and exacerbating the deadly opioid crisis that harmed so many Americans,” said Attorney General Paxton. “While nothing can restore the damage done, this settlement will provide Texans valuable resources to help prevent more opioid abuse. It was an honor to help lead these negotiations and I will never stop ensuring that justice is secured for those affected.” 

- Advertisement -

Attorney General Paxton has been a national leader in holding companies accountable for their roles in the opioid crisis, securing over $3 billion in settlements with Johnson & JohnsonWalmartWalgreensCVS, and other companies. 

Joining Attorney General Paxton in securing the settlement in principle are the attorneys general of California, Colorado, Connecticut, Delaware, Florida, Illinois, Massachusetts, New York, Oregon, Pennsylvania, Tennessee, Vermont, Virginia, and West Virginia.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Current Heart Attack Screening Tools Are Not Optimal and Fail to Identify Half the People Who Are at Risk

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at risk of having one, according to a new study led by Mount Sinai researchers.

Don’t Overfill Your Plate or Stomach

We’ve all been there: You’re gathered with family or friends for a delicious holiday meal. You start piling food on your plate, and before you know it, there’s no room left – and you haven’t even made it to the cranberry sauce and sweet potatoes.

UT Health San Antonio Center For Brain Health Celebrates with Ribbon Cutting

University of Texas System and UT San Antonio leaders today hailed “a new era of hope, healing and discovery” for neurological patients and their families with a ribbon-cutting for the UT Health San Antonio Center for Brain Health, a $100 million, 103,000-square-foot facility that will bring specialty care, therapy, diagnostics and research under one ro

Rare Mutation that Predicts Strong Immunotherapy Response in Colorectal Cancer Identified

A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations in the POLE gene is strongly associated with durable responses to immunotherapy in patients with metastatic colorectal cancer (CRC).
- Advertisement -
×